Skip to main content

Market Overview

FDA Approves Allergan's Ozurdex, Rejects Levadex

Share:

The FDA on Monday approved Allergan's (NYSE: AGN) diabetic macular edema (DME) drug Ozurdex.

Allergan's drug Levadex, a migraine treatment, was rejected by the FDA.

Wells Fargo analyst Larry Biegelsen is projecting a positive outcome for Allergan with its latest stage in development. With few cases of inflammation in DARPin, Biegelsen views DARPin as a plus, in comparison with Roche's Lucentis having none. Wells Fargo has an Outperform rating on Allergan and a price target in the range of $182 to $183.

Leerink analyst Seamus Fernandez says additional delay to Levadex is “frustrating,” removing $30 million of sales from 2014 and raises concerns on long-term peak sales.

Shares of Allergan are down 2.2 percent.

Latest Ratings for AGN

DateFirmActionFromTo
Apr 2020SunTrust Robinson HumphreyDowngradesBuyHold
Mar 2020CFRADowngradesBuyHold
Feb 2020SunTrust Robinson HumphreyMaintainsBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

 

Related Articles (AGN)

View Comments and Join the Discussion!

Posted-In: Larry Biegelsen Leerink Seamus Fernandez Wells FargoAnalyst Color News FDA Analyst Ratings

Latest Ratings

StockFirmActionPT
PPDBairdDowngrades48.0
OSPNSidoti & Co.Upgrades39.0
PLTSidoti & Co.Upgrades48.0
LRCXArgus ResearchMaintains725.0
ROSTLoop CapitalMaintains145.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com